La Jolla, California–(Newsfile Corp. – January 19, 2021) – Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).
Investing in Psychedelics Conference:
Date: Wednesday, January 20th, 2021
“We look forward to speaking on the Drug Developers Panel at this week’s Psychedelic Conference”, said Jim Kuo, CEO at TRYP Therapeutics. “As we move our development pipeline forward into the clinic, continuing to share our story with investors, expanding our shareholder base is critical to the growth of our company and we’re excited to participate in this event with a number of our peers”.
Investors or Shareholders interested in participating in this event can do so by registering at https://promo.cfnmedia.com/psychedelics .
Each live panel will last about 40 minutes with 15 minutes of Q&A. Panel #1 will begin just before 1:00pm EST, Panel #2 just before 2:00pm EST and Panel #3 just before 3:00pm EST.
- Panel 1. Drug Developers – Unlocking the Value Through IP (Tom Zuber, moderator)
- Panel 2. IP – Pitfalls and Potentials (Paul Rosen, moderator. David Wood is a panelist)
- Panel 3. Bankers and Capital Markets (Josh Lawler, moderator)
About Tryp Therapeutics:
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.
Tryp’s lead PFN™ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.
In addition to its PFN™ Program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.
For inquiries, please contact us at:
TRYP Investor Relations
T: 1-833-811-TRYP (8797)
Certain information in this news release, including statements relating to the anticipated date that the Common Shares will commence trading on the Canadian Securities Exchange constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the Prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.